SAS Output

21-AUG-2019 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization Surgery 20 15 11 7 0 0 SURV
      2 Randomization Non-surgical M 16 10 6 3 0 0  
      3 Patient Choice Surgery 65 18 10 2 0 0  
      4 Patient Choice Non-surgical M 100 0 0 0 0 0  
        201 43 27 12 0 0  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 708 169 54 15 5 3 CCD
      2 Site randomized: Control 595 228 115 55 19 4  
      3 SiteRand Int Risk: CSF 1157 512 311 147 41 8  
      4 SiteRand Int Risk: No CSF 880 385 190 95 33 6  
        3340 1294 670 312 98 21  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 635 342 186 87 31 12 BREAST
        635 342 186 87 31 12  
 
  2 Y 2 Observation 272 147 81 37 14 3  
      3 MK-3475 (Pembrolizumab) 267 146 83 39 11 2  
        539 293 164 76 25 5  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 138 112 55 29 13 1 SURV
        138 112 55 29 13 1  
 
  2 Y 1 Carvedilol 26 20 12 5 2 1  
      2 No prophylaxis 26 21 10 5 4 2  
      3 Observation 77 64 33 17 3 1  
        129 105 55 27 9 4  
 
S1600-Bladder,Radical Cystectomy Outcomes Nutrition 1 Y 1 Blinded Nutrition Drink 4 4 4 3 2 1 SXQOL
      2 Blinded Nutrition Drink 8 8 8 3 1 0  
        12 12 12 6 3 1  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 166 119 86 45 16 4 GU
      2 Tokyo-172 BCG 165 119 86 45 18 4  
      3 Prime + Tokyo-172 BCG 166 119 90 45 17 4  
        497 357 262 135 51 12  
 
S1614-HBV in Ca Pts, TAF vs SOC 1 Y   0 0 0 0 0 0 SXQOL
        0 0 0 0 0 0  
 
S1703-Met Breast, STM-monitoring v Usual Care 1 Y 0 Screening 67 67 41 21 5 2 CCD
        67 67 41 21 5 2  
 
  2 Y 1 Control (Usual Care) 16 16 15 9 2 1  
      2 Intervention (STMDDM) 16 16 15 8 2 1  
        32 32 30 17 4 2  
 
S1714-CIPN Risk Prediction Cohort Study, Taxanes 1 Y 1 Observation 35 35 35 33 18 3 SXQOL
        35 35 35 33 18 3  
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum 1 Y 0 Induction SST 87 87 52 25 12 3 GU
        87 87 52 25 12 3  
 
  2 Y 1 Standard Systemic Therapy Only 23 23 18 7 4 0  
      2 SST + Surgery/RT 25 25 19 11 6 2  
        48 48 37 18 10 2  
 
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab 1 Y 0 Initial Registration 9 9 9 9 6 2 GU
        9 9 9 9 6 2  
 
  2 Y 1 Chemo + RT 5 5 5 5 3 1  
      2 Chemo + RT + Atezolizumab 3 3 3 3 2 0  
        8 8 8 8 5 1  
 
S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD 1 Y   0 0 0 0 0 0 LYMPH
        0 0 0 0 0 0  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 576 78 58 22 1 0 PREV
        576 78 58 22 1 0  
 
  1 Y 1 Blinded drug 92 25 12 5 0 0  
      2 Blinded drug 36 0 0 0 0 0  
      3 Blinded drug 35 0 0 0 0 0  
      4 Blinded drug 87 16 8 5 3 1  
        250 41 20 10 3 1  
 

21-AUG-2019 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Open Studies with No Registrations
S1614-HBV in Ca Pts, TAF vs SOC regtype: 1
S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD regtype: 1